
Viridian Therapeutics, Inc.: updates and filings
Price
$29.96
November 20, 2026Market cap $3.4B
What Ploutos Investor adds for Viridian Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from 2013
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 4, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
August 2026
June 2026
May 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Aug 20, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jun 29, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 26, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jun 3, 2026Shareholder voteForm8-K
- May 28, 2026Material agreement endedForm8-K
- May 26, 2026Material agreement enteredForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 13, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- May 11, 2026Material agreement entered, new material financial obligation, other material eventsForm8-K
- May 8, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026FilingForm305B2
- May 5, 2026Regulation FD disclosureForm8-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Aug 20, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jun 29, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 26, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jun 3, 2026 | 8-K | Shareholder vote | Document |
| May 28, 2026 | 8-K | Material agreement ended | Document |
| May 26, 2026 | 8-K | Material agreement entered | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 13, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| May 11, 2026 | 8-K | Material agreement entered, new material financial obligation, other material events | Document |
| May 8, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | 305B2 | Filing | Document |
| May 5, 2026 | 8-K | Regulation FD disclosure | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 12, 2013.
The full analysis
What do Viridian Therapeutics's filings show?
The filings are where every one of Viridian Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.